Published data were identified by searches of MEDLINE using the search terms, “gastric cancer”, “surgery”, and “radiation”. We also searched the Proceedings of ASCO up to 2001. We paid most attention to prospective trials of preoperative radiation and postoperative chemoradiation for resected gastric cancer. Less weight was given to single-arm trials, trials for locally advanced or unresectable gastric cancer, and adjuvant chemotherapy.
ReviewChemoradiation for resectable gastric cancer
Section snippets
Disease progression
The primary treatment for gastric cancer is surgery. For example, in a study by Wanebo and colleagues, 77% of patients underwent surgery but only 35% of received adjuvant chemotherapy or radiation therapy.6 However, the National Cancer Database in the USA reported a lower proportion of patients who were treated with some type of surgery or surgery combined with adjuvant therapy;7 approximately 61–65% of patients with local–regional disease underwent surgery. Adjuvant chemotherapy, radiation, or
Patterns of relapse
Understanding patterns of disease relapse is crucial for designing appropriate adjuvant or preoperative therapy. Clinical and autopsy studies have revealed a high incidence of local–regional recurrence and distant relapse (primarily liver metastases and peritoneal seeding) after resection.12, 13, 14, 15, 16 Patients with primary cancer involving the gastroesophageal junction are more likely to have extra-abdominal spread, primarily lung metastases, than those whose cancer involved more distal
Adjuvant chemotherapy
The poor survival of patients who undergo curative resection alone for gastric cancer is indicative of the need for adjuvant therapy, especially in patients who have disease that has extended beyond the gastric wall and show lymph-node involvement at the time of surgery. Many phase II and III clinical trials have been done to find an effective adjuvant chemotherapy and several comprehensive reviews have been published on this topic. The combination of fluorouracil, doxorubicin, and mitomycin
Chemoradiation
The rationale for using chemoradiation as an adjuvant therapy for patients who have undergone R0 resection is that these patients are at risk for local–regional recurrence and distant metastases. Radiation in conjunction with surgery can improve local–regional control and systemic chemotherapy can suppress or eliminate microscopic distant metastasis and improve radiation cytotoxicity.
Chemotherapy may function as a radiosensitiser, improving the effect of radiation via various mechanisms. DNA is
Preoperative radiation
A randomised phase III trial from Beijing (China) has shown improved disease-free and overall survival rates and improved local–regional control when irradiation precedes resection for adenocarcinoma of the gastric cardia.46 Overall survival at 5 years were 30% in the 171 patients who received preoperative irradiation (40 Gy in 20 fractions over 4 weeks) and 20% in 199 patients who had only surgical resection (p=0·009). Local relapse was diagnosed in 39% of patients in the adjuvant irradiation
Conclusion
The large intergroup study clearly showed the value of postoperative chemoradiation. Further study is needed to develop more effective chemotherapy regimens. The advent of biological agents that target a specific cellular process provides a new avenue for further research. The use of chemotherapy as a radiosensitiser and systemic therapy need to be better defined. The concept of preoperative chemoradiation is attractive but remains investigational.
Search strategy and selection criteria
References (46)
- et al.
Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials
Eur J Cancer
(1999) - et al.
D2 dissection for gastric cancer
Surg Oncol
(1997) - et al.
Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist
Radiother Oncol
(1986) - et al.
Adenocarcinoma of the stomach: areas of failure in a reoperation series (second or symptomatic looks): clinicopathologic correlation and implications for adjuvant therapy
Int J Radiat Oncol Biol Phys
(1982) - et al.
Analysis of survival and local control following surgery for gastric cancer
Int J Radiat Oncol Biol Phys
(1990) - et al.
Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery
Int J Radiat Oncol Biol Physics
(1992) - et al.
Paclitaxel and concurrent radiation for gastric cancer
Int J Radiation Oncology Bio Phys
(2000) - et al.
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
Lancet
(1969) - et al.
Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial
Lancet
(1996) - et al.
Randomized clinical trial combination on the preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC)—report on 370 patients
Int J Radiat Oncol Biol Phys
(1998)